Business Context and Reporting Period
This Form 8-K filing by Revolution Medicines, Inc. (RVMD) reports corporate governance changes effective June 17, 2020. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Redwood City, California.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on board appointments and compensation program amendments.
Material Changes
- Board Composition: The Board of Directors increased in size from eight to nine members.
- Appointments: Peter Svennilson and Eric Schmidt, Ph.D., were appointed as independent directors effective immediately.
- Resignation: Larry Lasky, Ph.D., resigned from the Board on June 17, 2020, creating the vacancy filled by Mr. Svennilson.
- Committee Assignments: Mr. Svennilson joined the Nominating and Corporate Governance Committee; Dr. Schmidt joined the Audit Committee and was designated an audit committee financial expert.
Compensation and Governance Updates
The Board amended the Non-Employee Director Compensation Program to alter the mix of equity awards. Previously consisting entirely of stock options, the new structure grants approximately 70% in options and 30% in restricted stock units (RSUs).
- Initial Grants: New directors receive an option to purchase 25,318 shares and 7,234 RSUs upon appointment.
- Annual Grants: Directors serving at least four months receive an option for 12,659 shares and 3,617 RSUs at the annual meeting.
- Vesting: Initial options vest monthly over three years; initial RSUs vest quarterly over three years. Annual grants vest on the earlier of the first anniversary or the next annual meeting.
- Cash Compensation: Remains unchanged from the 2019 levels.
Investor Verification Points
- Verify the independence status of the new directors under Nasdaq listing standards.
- Review the impact of the equity mix change (70% options/30% RSUs) on future dilution and expense recognition.
- Confirm the specific vesting schedules for the Initial Options and RSUs granted to Mr. Svennilson and Dr. Schmidt.
- Note that entities affiliated with Mr. Svennilson's firm, The Column Group, hold 99,758 shares of Series C Preferred Stock purchased in June 2019.